Search Results
Found 2 results
510(k) Data Aggregation
(85 days)
BIONECT Hydrogel, Gauze Pads, Foam, Spray, and Clear Hydrogel are indicated for the dressing and munagement of minor burns: superficial cuts, lacerations, and abrasions; and minor irritations of the skin. A health care professional may be consulted prior to the first use of these products to delermine whether these conditions exist. BIONECT Hydrogel, Gauze Pads, Fourn, Spray, and Clear Hydrogel may also be used under the care of a health care professional for wounds such as partial to full thickness dermal ulcers (pressure ulcers, venous stasis ulcers, arterial ulcers, diabetic ulcers), surgical wounds (post-operative incisions and donor sites), and second degree burns.
BIONECT Hydrogel is propared from sodium hyaluronate and purified water to form a hydrogel dressing. Sodium hyaluronate is a polysaccharide biopolymer that can increase the viscosity of the gel. BIONECT® Hydrogel was designed to provide a soothing, moist environment that is supportive to wound healing.
The provided text describes the BIONECT® Hydrogel, and its substantial equivalence to predicate devices, rather than a study with specific acceptance criteria and detailed performance metrics. The information focuses on regulatory approval (510(k) summary) and intended use. Therefore, a direct answer to the request for acceptance criteria and a study proving device performance as typically expected from a clinical trial with statistical outcomes is not fully available in the provided text.
Based on the provided text, here's an attempt to answer the questions, highlighting what information is present and what is missing:
1. Table of acceptance criteria and the reported device performance
The provided document is a 510(k) summary and not a clinical study report. It focuses on demonstrating "substantial equivalence" of BIONECT® Hydrogel to already marketed predicate devices based on technological characteristics and intended use. Therefore, explicit, quantitatively defined "acceptance criteria" and direct, statistically reported "device performance" in the sense of a new clinical trial proving efficacy against a predefined benchmark are not presented. The "performance" is primarily described in terms of biocompatibility and safety, and by claiming equivalence to predicate devices.
Acceptance Criteria (Implied) | Reported Device Performance |
---|---|
Safety: Biocompatibility (cytotoxicity, dermal irritation, dermal sensitization) | Met: In vitro and in vivo biocompatibility testing performed in accordance with FDA recommendations (ISO-10993). These tests "all support the safe use of BIONECT® Hydrogel as a hydrogel temporary dressing in contact with breached or compromised skin." |
Met: Clinical experience in approximately 600 patients in 21 clinical trials (18 controlled) conducted in Europe indicates BIONECT® Cream (a related product) is safe for its intended use. (Note: This refers to BIONECT Cream, not directly Hydrogel, but is cited as supporting safety. Specific performance metrics like adverse event rates are not provided.) | |
Technological Equivalence: Form, occlusion, conformability, bioburden level, moist wound healing, appearance in the wound when hydrated vs. predicate devices. | Met: "The technological characteristics of the device such as form, occlusion, conformability, bioburden level, moist wound healing, and appearance in the wound when hydrated are not different from the predicate devices cited." |
Intended Use Equivalence: Indications for use being the same as predicate devices. | Met: "These indication statements are not different from the predicate device identified in paragraph (3) of this section." (Paragraph (3) refers to predicate devices like Argidene™ Gel, Carrasyn™ Hydrogel Wound Dressing, and DuoDERM Hydroactive™ Gel). |
2. Sample size used for the test set and the data provenance
- Test Set (for biocompatibility): Not explicitly stated. The document mentions "in vitro and in vivo biocompatibility testing" but doesn't provide specific sample sizes for these tests.
- Test Set (for clinical experience): "approximately 600 patients with various types of ulcers, burns, and surgical wounds" across "21 clinical trials (18 controlled)".
- Data Provenance: Europe (for the clinical experience cited). The text does not specify retrospective or prospective. Given they are "clinical trials," they are typically prospective, but this is not explicitly stated.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
The document does not provide this information. The clinical experience cited (from Europe) is referred to generally in support of safety, not as a ground-truthed test set for a specific AI or diagnostic device.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
The document does not provide this information.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
No such study is mentioned or implied. This device (BIONECT® Hydrogel) is a wound dressing, not an AI-assisted diagnostic or imaging device that would typically involve human readers.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
Not applicable. BIONECT® Hydrogel is a physical wound dressing, not an algorithm.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
For the biocompatibility tests, the ground truth would be established by the biological responses observed in the in vitro and in vivo models according to established standards. For the clinical experience (cited for safety), "outcomes data" related to safety (e.g., adverse events) would be the ground truth, though details aren't provided.
8. The sample size for the training set
Not applicable. This is a medical device (wound dressing), not a machine learning model, so there is no "training set."
9. How the ground truth for the training set was established
Not applicable.
Summary of Limitations from the Text:
The provided text is a 510(k) Premarket Notification summary for a wound dressing. Its purpose is to demonstrate substantial equivalence to existing devices for regulatory approval, primarily based on safety and similar technological characteristics, not to present a detailed clinical study with performance criteria for a novel device or AI. Therefore, most of the specific questions related to acceptance criteria, sample sizes for test/training sets, expert involvement, and advanced study designs (like MRMC) as commonly discussed for AI/diagnostic devices are not addressed in this type of document.
Ask a specific question about this device
(194 days)
BIONECT® Cream is indicated for the dressing and management of partial to full thickness dermal ulcers (pressure sores, venous stasis ulcers, arterial ulcers, diabetic ulcers), wounds including cuts, abrasions, donor sites, and post-operative incisions, irritations of the skin, and first and second degree burns. The dressing is intended to cover a wound or burn on a patient's skin, and protect against abrasion, friction, and desiccation.
BIONECT® Cream acts to provide a moist wound environment and protect the wound. BIONECT® Cream was designed to provide a soothing, moist environment for easy application to various types of wounds as a hydrogel dressing. BIONECT® Cream is prepared from sodium hyaluronate and purified water to form a hydrogel dressing. Sodium hyaluronate is a polysaccharide biopolymer that can increase the viscosity of the gel. BIONECT® Cream was designed to provide a moist wound healing environment.
The provided text describes a medical device called BIONECT® Cream, a hyaluronic acid sodium salt hydrogel dressing. It mainly focuses on its description, intended use, and comparison to predicate devices, rather than a detailed study with acceptance criteria often seen for AI/ML devices.
Therefore, many of the requested sections (e.g., sample size for test set, number of experts, adjudication methods, MRMC studies, standalone performance, training set details) are not applicable (N/A) based on the provided document as they relate to performance evaluation methodologies for AI/ML or complex diagnostic devices, which BIONECT® Cream is not.
Here's the information that can be extracted from the provided text:
1. A table of acceptance criteria and the reported device performance
Acceptance Criteria | Reported Device Performance |
---|---|
Biocompatibility: Safe use as a hydrogel temporary dressing in contact with breached or compromised skin. | Biocompatibility testing has been performed as recommended in the "Draft Guidance for the Preparation of a Premarket Notification for a Non-Interactive Wound and Burn Dressing." These tests all support the safe use of BIONECT® Cream. |
Safety for intended use: Clinical evidence validating safety for dressing and management of various wounds and burns. | Clinical experience in approximately 600 patients with various types of ulcers, burns, and surgical wounds in 21 clinical trials (18 controlled) conducted in Europe indicates that BIONECT® Cream is safe for its intended use. |
2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
- Sample size: Approximately 600 patients.
- Data provenance: Conducted in Europe across 21 clinical trials (18 controlled). The text does not explicitly state if the trials were retrospective or prospective, but clinical trials are generally prospective.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
- N/A. The assessment relies on clinical trials and biocompatibility testing, not on establishing ground truth via expert consensus in the way an AI/ML diagnostic would for a test set. The "experts" involve the clinicians conducting the trials, but their roles in "establishing ground truth" for a specific test set, as defined for AI/ML, are not applicable here.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
- N/A. This concept is specific to resolving discrepancies in expert labeling or diagnoses for test sets, which is not relevant to the evaluation of a wound dressing.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- N/A. This type of study is relevant for AI-assisted diagnostic devices, not for a wound dressing.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
- N/A. This is a wound dressing, not an algorithm.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
- The "ground truth" for safety and intended use was established through:
- Biocompatibility testing: Standardized tests demonstrating material safety.
- Clinical outcomes data: Observation of patient outcomes and safety profiles in clinical trials involving approximately 600 patients with various wounds and burns.
8. The sample size for the training set
- N/A. This device does not involve a "training set" in the context of machine learning.
9. How the ground truth for the training set was established
- N/A. This device does not involve a "training set" in the context of machine learning.
Ask a specific question about this device
Page 1 of 1